1074-85-7

Usage

Uses

Used in Pharmaceutical Industry:
Indole-4-methanol is used as a key intermediate for the synthesis of various pharmaceuticals and bioactive compounds. Its unique chemical structure and properties make it a valuable component in the development of new drugs and therapeutic agents.
Used in Agrochemical Industry:
Indole-4-methanol is used as a precursor in the biosynthesis of the plant hormone auxin, which plays a crucial role in plant growth and development. This application contributes to the advancement of agricultural practices and crop yield enhancement.
Used in Biochemical Research:
Indole-4-methanol is used as a subject of study in biochemical research due to its potential antioxidant, antimicrobial, and anti-inflammatory properties. Its exploration in these areas can lead to the discovery of new therapeutic agents and contribute to the understanding of various biological processes.
Used in Antioxidant Applications:
Indole-4-methanol is used as an antioxidant agent, which can help protect cells from oxidative damage and contribute to the prevention of various diseases and conditions associated with oxidative stress.
Used in Antimicrobial Applications:
Indole-4-methanol is used as an antimicrobial agent, exhibiting activity against various microorganisms. This property can be utilized in the development of new antimicrobial drugs and treatments.
Used in Anti-inflammatory Applications:
Indole-4-methanol is used as an anti-inflammatory agent, which can help reduce inflammation and alleviate symptoms associated with inflammatory conditions. Its potential in this area can lead to the development of new treatments for various inflammatory diseases.

InChI:InChI=1/C9H9NO/c11-6-7-2-1-3-9-8(7)4-5-10-9/h1-5,10-11H,6H2

Upstream product

• 39830-66-5 methyl 1H-indole-4-carboxylate 
• 50614-84-1 ethyl indole-4-carboxylate 
• 67-56-1 methanol 
• 81251-05-0 3-hydroxy-5-nitroisochroman 
• 74068-99-8 (1H-Indol-4-ylmethyl)-dimethyl-amine 
• 75446-77-4 4-aminomethylindole 
• 1975-50-4 2-methyl-3-nitrobenzic acid 
• 4637-24-5 N,N-dimethyl-formamide dimethyl acetal 
• 77747-69-4 5-nitro-1H-isochromen-1-one 
• 77747-70-7 3,4-dihydro-3-methoxy-5-nitroisocoumarin 
• 59382-59-1 2-methyl-3-nitro-benzoic acid methyl ester 
• 73816-11-2 Methyl trans-2-<β-(dimethylamino)vinyl>-3-nitrobenzoate 
• 42792-95-0 2-methyl-5-nitroisoquinolin-2-ium iodide 
• 3468-22-2 (1H-indol-4-yl)-N-methylmethanamine 

Downstream Products

• 862297-60-7 4-[(tert-butyldiphenylsilyloxy)methyl]indole 
• 1074-86-8 4-formyl indole 
• 98664-90-5 ethyl (6aRS,9SR,9aSR)-hexahydro-7,7-dimethylisoindolo[4,5,6-cd]indole-9-carboxylate 
• 905274-11-5 indolin-4-ylmethanol 
• 30933-66-5 4-(cyanomethyl)indole 
• 68900-05-0 4-vinylindole 
• 146175-98-6 N-benzyl-4-(2-methoxyvinyl)-3-(3'-trimethylsilylmethyl-2'-hydroxy-but-3'-enyl)indoline 
• 146175-96-4 N-benzyl-3-cyanomethyl-4-(2-methoxyvinyl)indoline 
• 146175-97-5 N-benzyl-3-formylmethyl-4-(2-methoxyvinyl)indoline 
• 49839-99-8 4-(2-nitrovinyl)indole 
• 16176-73-1 2-(1H-indol-4-yl)ethan-1-amine 

Relevant academic research and scientific papers

4,5,6,7-TETRAHYDRO-1 H-PYRAZOLO[4,3-C]PYRIDIN-3-AMINE COMPOUNDS AS CBP AND/OR EP300 INHIBITORS

The present invention relates to compounds of formula (I) or formula (II): and to salts thereof, wherein R1-R4 of formula (I) and R1-R3 of formula (II) have any of the values defined herein, and compositions and uses thereof. The compounds are useful as inhibitors of CBP and/or EP300. Also included are pharmaceutical compositions comprising a compound of formula (I) of formula (II) or a pharmaceutically acceptable salt thereof, and methods of using such compounds and salts in the treatment of various CBP and/or EP300-mediated disorders.

A total synthesis of (±)-α-cyclopiazonic acid using a cationic cascade as a key step

The indole alkaloid α-cyclopiazonic acid 1 has been synthesised by a route, which features at its core an acid-catalysed cationic cascade cyclisation terminated by a sulfonamide group.

The Knight route to cyclopiazonic acid: Enantioselective synthesis of a key intermediate

The indole alkaloid α-cyclopiazonic acid (CPA) is one of the few known inhibitors of sarco(endo)plasmic reticulum Ca2+-ATPase (SERCA) besides thapsigargin and artemisinin. Inhibitors of SERCA hold promise as novel anticancer and antimalarial drugs. Since its structure elucidation three racemic syntheses of α-cyclopiazonic acid have been published. We report now the first enantioselective and high yielding synthesis of a key-intermediate of the Knight synthesis, currently the most efficient route to CPA. Our synthesis is based on a diastereoselective 1,4-cuprate addition followed by an enolate azidation of an indolylacrylic acid modified with the Evans auxiliary.

THERAPEUTIC AGENTS, AND METHODS OF MAKING AND USING THE SAME

In part, the present invention is directed to antibacterial compounds

Novel 4-phenyl substituted tetrahydroisoquinolines and therapeutic use thereof

The present invention relates to a method of treating disorders including cognition impairment, generalized anxiety disorder, acute stress disorder, social phobia, simple phobias, pre-menstrual dysphoric disorder, social anxiety disorder, major depressive

Novel 4-phenyl substituted tetrahydroiso quinolines therapeutic use thereof

Compounds are provided that, by way of their selective neurotransmitter binding useful for the treatment of various neurological and psychological disorders, e.g., ADHD. Such compounds are 4-phenyl substituted tetrahydroisoquinolines having the Formula IA, IB, IIA, IIB, IIIA or IIIC as set forth herein.

Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6-tetramethylbenzyl)-1h-indol-4ylmethylene]hydrazide

Highly potent human glucagon receptor (hGluR) antagonists have been prepared employing both medicinal chemistry and targeted libraries based on modification of the core (proximal) dimethoxyphenyl group, the benzyl ether linkage, as well as the (distal) benzylic aryl group of the lead 2, 3-cyano-4-hydroxybenzoic acid (3,5-dimethoxy-4-isopropylbenzyloxybenzylidene)hydrazide. Electron-rich proximal aryl moieties such as mono- and dimethoxy benzenes, naphthalenes, and indoles were found to be active. The SAR was found to be quite insensitive regarding the linkage to the distal aryl group, since long and short as well as polar and apolar linkers gave highly potent compounds. The presence of a distal aryl group was not crucial for obtaining high binding affinity to the hGluR. In many cases, however, the affinity could be further optimized with substituted distal aryl groups. Representative compounds have been tested for in vitro metabolism, and structure - metabolism relationships are described. These efforts lead to the discovery of 74, NNC 25-2504, 3-cyano-4-hydroxybenzoic acid [1-(2,3,5,6tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide, with low in vitro metabolic turnover. 74 was a highly potent noncompetitive antagonist of the human glucagon receptor (IC50 = 2.3 nM, KB = 760 pM) and of the isolated rat receptor (IC50 = 430 pM, KB = 380 pM). Glucagonstimulated glucose production from isolated primary rat hepatocytes was inhibited competitively by 74 (Ki = 14 nM). This compound was orally available in dogs (Fpo = 15%) and was active in a glucagon-challenged rat model of hyperglucagonemia and hyperglycemia.

Dehydroamino acids

Compounds of formula 1 and 1-1, wherein R1 is hydrogen, hydroxy, amino or halogen, R2 is hydrogen, hydroxy, or halogen and R3 is hydrogen (Formula 1) or R1 is hydrogen and R2 and R3 taken together with the ethenylene group connecting them form phenyl, pyrrole, pyrroline, oxopyrroline, pyrazole, triazole, or imidazole (Formula 1-1), A is R4 R5 are hydrogen, methyl, ethyl or halogen except that R4 r5 cannot both be hydrogen; and 1) B is hydrogen, or lower alkyl; or 2) B is where R6 R7 R8 and R9 are independently hydrogen, hydroxy, aminosulfonyl, halogen, lower alkoxy, cyano, amino, lower alkyl, lower alkyl amino, or nitro; or 3) B is where R10 is hydrogen, hydroxy, halogen, or lower alkyl and C is a five- or six- membered ring with 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur, which ring may be unsubstituted or mono- or di- substituted with lower alkyl, cycloalkyl, amino, or substituted amino; 4) B is where X and Y are independently methylene or nitrogen; or 5) B is where at leat one of T, U, V, or W is nitrogen, and any of T, U, V or W which is carbon may be substituted with lower alkyl, lower alkyl amino, lower alkoxy, hydroxy, aminosulfonyl, halogen, cyano, amino, or nitro; or 6) B is where Y is carbon or nitrogen; or 7) B is a five-membered aromatic ring with 1 to 3 heteratoms selected from nitrogen, oxygen, and sulfur which ring may be unsubstituted or mono- or di-substituted with lower alkyl, cycloalky, trifluoroloweralkyl, amino, halogen, substituted amino, or which ring may be fused with a 5 or 6 membered aromatic ring containing 0 to 3 heteroatoms which heteroatoms are selected from nitrogen, oxygen, and sulfur; and pharmaceutically acceptable salts thereof, and related prodrugs, pharmaceutical compositions and methods of treatment, which compounds are useful for treating psoriasis.

Diaminopropionic acid derivatives

A compound of formula 1a which is useful for treating reperfusion injury, and salts, prodrugs, and related compounds.

Azepinoindole derivatives with high affinity for brain dopamine and serotonin receptors

We synthesized 20 and 21 as conformationally constrained analogues of the dopamine receptor antagonist SKF-83742, as well as analogues 6-9, 16, and 18-22. Although 20 and 21 were inactive, 7, 9, and 19 showed strong binding to D-1, D-2, S-2, and α-1 receptors, as well as antipsychotic activity in vivo.